Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 151,359	$ 541,835
Accounts receivable, net of allowances of approximately $7.1 million and $2.9 million at December 31, 2017 and December 31, 2016, respectively	3,496	18,171
Inventory, net	5,559	28,486
Prepaid expenses and other current assets	11,688	14,875
Current assets held for sale	391,202	50,586
Total current assets	563,304	653,953
Fixed assets, net	17,254	30,961
In-process research & development	0	65,000
Amortizable intangible assets, net	0	257,185
Goodwill	200,571	200,571
Restricted cash	5,541	5,032
Contingent purchase price from sale of businesses	80,700	143,700
Other assets	5,613	715
Noncurrent assets held for sale	0	348,094
Total assets	872,983	1,705,211
Current liabilities:
Accounts payable	10,244	20,578
Accrued expenses	95,197	66,838
Current portion of contingent purchase price	4,995	0
Convertible senior notes	0	53,749
Deferred revenue	4,476	16,435
Current liabilities held for sale	60,580	87,025
Total current liabilities	175,492	244,625
Contingent purchase price	14,655	31,832
Convertible senior notes	649,198	623,584
Deferred tax liabilities	0	89,992
Other liabilities	8,724	11,705
Noncurrent liabilities held for sale	0	50,457
Total liabilities	848,069	1,052,195
Equity component of currently redeemable convertible senior notes (Note 9)	0	1,033
Stockholders’ equity:
Preferred stock, $1.00 par value per share, 5,000,000 shares authorized; no shares issued and outstanding	0	0
Common stock, $0.001 par value per share, 187,500,000 authorized; 76,191,958 issued and 73,178,815 outstanding at December 31, 2017 and 73,212,545 issued and 71,019,563 outstanding at December 31, 2016	76	73
Additional paid-in capital	1,377,393	1,256,890
Treasury stock, at cost; 3,013,143 and 2,192,982 shares at December 31, 2017 and December 31, 2016, respectively	(90,016)	(50,000)
Accumulated deficit	(1,257,356)	(548,983)
Accumulated other comprehensive loss	(5,183)	(5,479)
Total The Medicines Company stockholders’ equity	24,914	652,501
Non-controlling interest in joint venture	0	(518)
Total stockholders’ equity	24,914	651,983
Total liabilities and stockholders’ equity	872,983	1,705,211
In-process research and development [Member]
Current assets:
In-process research & development	0	65,000
Product licenses [Member]
Current assets:
Amortizable intangible assets, net	0	26,987
Developed product rights [Member]
Current assets:
Amortizable intangible assets, net	$ 0	$ 230,198